Koninklijke Philips NV 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NYSE
Royal Philips reported a significant financial turnaround in 2025 with increased comparable sales and expanded margins, despite ongoing Respironics recall litigation and a complex global environment.
NYSE
Philips' 20-F filing highlights progress in its three-year plan, strong profitability improvement, and ongoing efforts to resolve the Respironics recall, while facing challenges in China.
NYSE
Royal Philips details the service contract for its CFO, Mr. A. Bhattacharya, outlining compensation, terms of engagement, and other key provisions effective from May 9, 2023.